xmlui.ArtifactBrowser.ConfigurableBrowse.title.metadata.subject_decs
Ara mostrant els elements 1-20 d 29
-
A Phase I Dose-Escalation Study of LY3405105, a Covalent Inhibitor of Cyclin-Dependent Kinase 7, Administered to Patients With Advanced Solid Tumors
(Oxford University Press, 2024-01) -
A Phase Ib Study of the DNA-PK Inhibitor Peposertib Combined with Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal Cancer
(American Association for Cancer Research, 2024-02-15) -
A pragmatic guide for management of adverse events associated with lorlatinib
(Elsevier, 2024-03-14) -
Current perspectives on the management of patients with advanced RET-driven thyroid cancer in Europe
(Frontiers Media, 2023-05-03) -
DSTYK inhibition increases the sensitivity of lung cancer cells to T cell–mediated cytotoxicity
(Rockefeller University Press, 2022-12-05) -
Hepatic Rupture as the Initial Presentation of an EGFR-Mutated Lung Adenocarcinoma: A Case Report
(Frontiers Media, 2022-03) -
High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer
(Nature Portfolio, 2022-09-07) -
Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance
(American Association for Cancer Research, 2022-10-15) -
INK4 Tumor Suppressor Proteins Mediate Resistance to CDK4/6 Kinase Inhibitors
(American Association for Cancer Research, 2022-02-01) -
LIBRETTO-531: a phase III study of selpercatinib in multikinase inhibitor-naïve RET-mutant medullary thyroid cancer
(Future Medicine, 2022-09)